Rodger L Bick

Summary

Affiliation: University of Texas Southwestern Medical Center
Country: USA

Publications

  1. ncbi request reprint Disseminated intravascular coagulation current concepts of etiology, pathophysiology, diagnosis, and treatment
    Rodger L Bick
    Department of Medicine and Pathology, University of Texas Southwestern Medical Center, 10455 North Central Expressway, Suite 109 PMB320, Dallas, TX 75231, USA
    Hematol Oncol Clin North Am 17:149-76. 2003
  2. doi request reprint Treatment options for patients who have antiphospholipid syndromes
    Rodger L Bick
    Hematol Oncol Clin North Am 22:145-53, viii. 2008
  3. ncbi request reprint Thromboprophylaxis in surgical patients
    Rodger L Bick
    Dallas Thrombosis Hemostatis and Vascular Medicine Clinical Center, Dallas, Texas, USA
    Eur J Med Res 9:104-11. 2004
  4. ncbi request reprint Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use
    Rodger L Bick
    Department of Medicine, University of Texas Southwestern Medical School, 2201 Inwood Road, Dallas, TX 75235 8852, USA
    Hematol Oncol Clin North Am 19:1-51, v. 2005
  5. ncbi request reprint Recurrent miscarriage syndrome and infertility due to blood coagulation protein/platelet defects: a review and update
    Rodger L Bick
    University of Texas Southwestern Medical Center, Dallas, Texas 75231, USA
    Clin Appl Thromb Hemost 11:1-13. 2005
  6. doi request reprint Antiphospholipid syndromes
    Rodger L Bick
    Hematol Oncol Clin North Am 22:xiii-xiv. 2008
  7. ncbi request reprint Cancer-associated thrombosis: focus on extended therapy with dalteparin
    Rodger L Bick
    University of Texas Southwestern Medical Center, Dallas 93035, USA
    J Support Oncol 4:115-20. 2006
  8. ncbi request reprint Hereditary and acquired thrombophilic disorders
    Rodger L Bick
    University of Texas Southwestern Medical Center, Dallas, USA
    Clin Appl Thromb Hemost 12:125-35. 2006
  9. ncbi request reprint Thromboprophylaxis and thrombosis in medical, surgical, trauma, and obstetric/gynecologic patients
    Rodger L Bick
    Department of Medicine and Pathology, University of Texas Southwestern Medical Center, 10455 North Central Expressway, Suite 109 PMB320, Dallas, TX 75231, USA
    Hematol Oncol Clin North Am 17:217-58. 2003
  10. ncbi request reprint Antiphospholipid thrombosis syndromes
    Rodger L Bick
    Department of Medicine and Pathology, University of Texas Southwestern Medical Center, 10455 North Central Expressway, Suite 109 PMB320, Dallas, TX 75231, USA
    Hematol Oncol Clin North Am 17:115-47. 2003

Detail Information

Publications37

  1. ncbi request reprint Disseminated intravascular coagulation current concepts of etiology, pathophysiology, diagnosis, and treatment
    Rodger L Bick
    Department of Medicine and Pathology, University of Texas Southwestern Medical Center, 10455 North Central Expressway, Suite 109 PMB320, Dallas, TX 75231, USA
    Hematol Oncol Clin North Am 17:149-76. 2003
    ....
  2. doi request reprint Treatment options for patients who have antiphospholipid syndromes
    Rodger L Bick
    Hematol Oncol Clin North Am 22:145-53, viii. 2008
    ..This article also reviews the clinical presentations associated with each of these six subgroups...
  3. ncbi request reprint Thromboprophylaxis in surgical patients
    Rodger L Bick
    Dallas Thrombosis Hemostatis and Vascular Medicine Clinical Center, Dallas, Texas, USA
    Eur J Med Res 9:104-11. 2004
    ..Orthopedic surgical thromboprophylaxis has intentionally been deleted, as this topic is well covered in other articles in this issue (EurJ Med Res 9(3), March 2004)...
  4. ncbi request reprint Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use
    Rodger L Bick
    Department of Medicine, University of Texas Southwestern Medical School, 2201 Inwood Road, Dallas, TX 75235 8852, USA
    Hematol Oncol Clin North Am 19:1-51, v. 2005
    ..Despite these significant developments, heparin and heparin-derived drugs have continued to play a major role in the management of thrombotic and cardiovascular disorders...
  5. ncbi request reprint Recurrent miscarriage syndrome and infertility due to blood coagulation protein/platelet defects: a review and update
    Rodger L Bick
    University of Texas Southwestern Medical Center, Dallas, Texas 75231, USA
    Clin Appl Thromb Hemost 11:1-13. 2005
    ..The success rate of normal term delivery in these 312 patients was 94% using ASA + heparin or Dalteparin. In addition, side effects of therapy were minimal...
  6. doi request reprint Antiphospholipid syndromes
    Rodger L Bick
    Hematol Oncol Clin North Am 22:xiii-xiv. 2008
  7. ncbi request reprint Cancer-associated thrombosis: focus on extended therapy with dalteparin
    Rodger L Bick
    University of Texas Southwestern Medical Center, Dallas 93035, USA
    J Support Oncol 4:115-20. 2006
    ....
  8. ncbi request reprint Hereditary and acquired thrombophilic disorders
    Rodger L Bick
    University of Texas Southwestern Medical Center, Dallas, USA
    Clin Appl Thromb Hemost 12:125-35. 2006
  9. ncbi request reprint Thromboprophylaxis and thrombosis in medical, surgical, trauma, and obstetric/gynecologic patients
    Rodger L Bick
    Department of Medicine and Pathology, University of Texas Southwestern Medical Center, 10455 North Central Expressway, Suite 109 PMB320, Dallas, TX 75231, USA
    Hematol Oncol Clin North Am 17:217-58. 2003
    ..00 dollars (= 30% of 1,168,500.00 dollars) in savings per 100 patients...
  10. ncbi request reprint Antiphospholipid thrombosis syndromes
    Rodger L Bick
    Department of Medicine and Pathology, University of Texas Southwestern Medical Center, 10455 North Central Expressway, Suite 109 PMB320, Dallas, TX 75231, USA
    Hematol Oncol Clin North Am 17:115-47. 2003
    ....
  11. ncbi request reprint Disseminated intravascular coagulation: a review of etiology, pathophysiology, diagnosis, and management: guidelines for care
    Rodger L Bick
    University of Texas Southwestern Medical Center, Dallas Thrombosis Hemostasis Clinical Center, ThromboCare Laboratories, 75231, USA
    Clin Appl Thromb Hemost 8:1-31. 2002
    ..At present, treatment of the triggering event, low-dose heparin or antithrombin concentrate and wise choice of components when indicated appear to be the most effective modes of therapy...
  12. ncbi request reprint Thrombophilic causes of retinal vascular thrombosis: etiology and treatment outcomes
    Rodger L Bick
    Department of Medicine, University of Texas Southwestern Medical Center, Dallas Thrombosis Hemostasis and Vascular Medicine Clinical Center, Dallas, Texas, 75231, USA
    Clin Appl Thromb Hemost 8:315-8. 2002
  13. ncbi request reprint Thrombosis and thrombophilia: diagnosis and management
    Rodger L Bick
    University of Texas Southwestern Medical Center, Dallas 75231, USA
    Hematol Oncol Clin North Am 17:xi-xii. 2003
  14. ncbi request reprint Introduction to thrombosis proficient and cost-effective approaches to thrombosis
    Rodger L Bick
    Department of Medicine and Pathology, University of Texas Southwestern Medical Center, 10455 North Central Erpressway, Suite 109 PMB320, Dallas, TX 75231, USA
    Hematol Oncol Clin North Am 17:1-8, v. 2003
    ..Yet many, if not most, episodes of thrombosis can be prevented by appropriate primary antithrombotic therapy, and most recurrences can be prevented by the appropriate choice of secondary therapy...
  15. ncbi request reprint Prothrombin G20210A mutation, antithrombin, heparin cofactor II, protein C, and protein S defects
    Rodger L Bick
    Department of Medicine and Pathology, University of Texas Southwestern Medical Center, 10455 North Central Expressway, Suite 109 PMB320, Dallas, TX 75231, USA
    Hematol Oncol Clin North Am 17:9-36. 2003
    ..Assessment of prothrombin gene mutation should be part of the primary evaluation of patients with unexplained thrombosis...
  16. ncbi request reprint Antithrombotic therapy: current practice and future trends
    Rodger L Bick
    Department of Medicine, University of Texas Southwestern Medical Center, Dallas Thrombosis Hemostasis Clinical Center, 10455 North Central Expressway, Suite 109, PMB 320, Dallas, TX 75231, USA
    Hematol Oncol Clin North Am 19:xi-xvi. 2005
  17. ncbi request reprint Cancer-associated thrombosis
    Rodger L Bick
    Dallas Thrombosis Hemostasis Clinical Center, University of Texas Southwestern Medical School, Dallas, USA
    N Engl J Med 349:109-11. 2003
  18. ncbi request reprint Management of venous thrombosis and thromboembolism: prevention and treatment
    Rodger L Bick
    University of Texas Southwestern Medical Center, Dallas Thrombosis Hemostasis Difficult Hematology Clinical Center, USA
    Surg Technol Int 10:226-36. 2002
    ..Thrombosis, therefore, accounts for extraordinary morbidity, mortality, and cost of medical care...
  19. doi request reprint Laboratory evaluation of the antiphospholipid syndrome
    Debra A Hoppensteadt
    Department of Pathology, Stritch School of Medicine, Loyola University Chicago, 2160 S First Avenue, Maywood, IL 60153, USA
    Hematol Oncol Clin North Am 22:19-32, v. 2008
    ..This article describes the laboratory diagnosis of APLS, including the detection of lupus anticoagulants, anticardiolipin antibodies, and subtypes of antiphospholipid antibodies...
  20. doi request reprint The clinical spectrum of antiphospholipid syndrome
    William F Baker
    David Geffen School of Medicine, Center for Health Sciences, University of California, Los Angeles, Los Angeles, CA, USA
    Hematol Oncol Clin North Am 22:33-52, v-vi. 2008
    ..Microangiopathic APS may present with isolated tissue and organ injury or as the overwhelming "thrombotic storm" observed in catastrophic APS...
  21. doi request reprint Antiphospholipid syndrome in pregnancy
    Rodger L Bick
    Hematol Oncol Clin North Am 22:107-20, vii. 2008
    ..It presents the outcomes of the author's protocol and those of others in treating women who have antiphospholipid syndrome and who have suffered recurrent miscarriages...
  22. ncbi request reprint Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis
    Jawed Fareed
    Departments of Pathology and Pharmacology, Hemostasis and Thrombosis Research Laboratories, Loyola University Chicago, Maywood, Illinois 60153, USA
    Semin Thromb Hemost 30:89-104. 2004
    ..These agents may not have the broad clinical spectrum as that observed with the heparins. More recently, several pharmaceutical companies have produced generic LMWHs...
  23. ncbi request reprint Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent
    Jeanine M Walenga
    Department of Pathology, Loyola University Medical Center, 2160 S First Avenue, Maywood, Illinois 60153, USA
    Expert Opin Investig Drugs 11:397-407. 2002
    ..At present, laboratory monitoring is not recommended. Clinical trials for treatment of established thrombosis, coronary syndromes and adjunct to thrombolytic therapy are in progress...
  24. ncbi request reprint Management of thrombotic and cardiovascular disorders in the new millenium
    Jawed Fareed
    Hemostasis and Thrombosis Research Unit, Loyola University Medical Center, Maywood, Illinois 60153, USA
    Clin Appl Thromb Hemost 9:101-8. 2003
    ....
  25. ncbi request reprint Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation
    Debra Hoppensteadt
    Hemostasis and Thrombosis Research Laboratories, Department of Pathology and Pharmacology, Loyola University Medical Center, 2160 South First Avenue, Maywood, IL 60153, USA dhoppen lumc edu
    Hematol Oncol Clin North Am 17:313-41. 2003
    ..Ultra-LMWHs and synthetic heparinomimetics, such as fondaparinux, that exhibit a narrow pharmacologic spectrum will only be useful in specific indications and in combination with other drugs...
  26. doi request reprint Controversies and unresolved issues in antiphospholipid syndrome pathogenesis and management
    William F Baker
    David Geffen School of Medicine, Center for Health Sciences, University of California, Los Angeles, Los Angeles, CA, USA
    Hematol Oncol Clin North Am 22:155-74, viii. 2008
    ..This article summarizes the clinical questions remaining to be answered and debates concerning pathogenesis, diagnosis, and management...
  27. doi request reprint The immunogenic potential of generic version of low-molecular-weight heparins may not be the same as the branded products
    Jawed Fareed
    Clin Appl Thromb Hemost 14:5-7. 2008
  28. ncbi request reprint Potential thrombogenic complications with the use of recombinant activated factor VII in combat trauma
    Jawed Fareed
    Clin Appl Thromb Hemost 13:121-3. 2007
  29. ncbi request reprint Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications
    Jyothi Maddineni
    Department of Pharmacology, Loyola University Medical Center, Maywood, IL 60153, USA
    Clin Appl Thromb Hemost 12:267-76. 2006
    ....
  30. ncbi request reprint Argatroban and lepirudin: clinical trials to clinical practice
    Harry L Messmore
    Clin Appl Thromb Hemost 11:367-9. 2005
  31. ncbi request reprint Generic low molecular weight heparins: a significant dilemma
    Jawed Fareed
    Clin Appl Thromb Hemost 11:363-6. 2005
  32. ncbi request reprint Development of generic low molecular weight heparins: a perspective
    Jawed Fareed
    Department of Pathology, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153, USA
    Hematol Oncol Clin North Am 19:53-68, v-vi. 2005
    ..Some objective guidelines for the proper development of these drugs are needed. Only expert groups and advisory panels to the regulatory bodies can develop these guidelines...
  33. ncbi request reprint Generic low-molecular-weight heparins: some practical considerations
    Jawed Fareed
    Department of Pathology, Loyola University Chicago, Maywood, IL 60153, USA
    Semin Thromb Hemost 30:703-13. 2004
    ..Thus, until the establishment of valid regulatory guidelines for the generic interchangeability of the commercially available LMWHs is completed, generic substitutes are not recommended...
  34. ncbi request reprint Epilogue. Expanded role of low-molecular-weight heparins in hematology and oncology
    Debra A Hoppensteadt
    Departments of Pathology and Pharmacology, Loyola University Chicago, Maywood, Illinois, USA
    Semin Thromb Hemost 30:105-8. 2004
  35. ncbi request reprint Are the current guidelines for the acceptance of generic low molecular weight heparins adequate?
    J Fareed
    Clin Appl Thromb Hemost 9:269-72. 2003
  36. ncbi request reprint Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other adverse effects of heparin-type therapy
    Jeanine M Walenga
    Department of Thoracic Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL 60153, USA
    Hematol Oncol Clin North Am 17:259-82, viii-ix. 2003
    ..Most attention is devoted to heparin-induced thrombocytopenia, as it is the most clinically aggressive adverse reaction. Additionally, less common and several newly reported side effects are discussed...
  37. ncbi request reprint Contaminant in the recalled unfractionated heparin preparations: where is the problem?
    Debra A Hoppensteadt
    Clin Appl Thromb Hemost 14:261-6. 2008